Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Feb 12, 2017 3:19pm
158 Views
Post# 25834647

RE:RE:RE:RE:J & J XARELTO

RE:RE:RE:RE:J & J XARELTO
XARELTO  that is used for other medical ailments as we see advertised on TV, is it one and the same thing used in the COMPASS trial?
 
Yes, Xarleto used in COMPASS is the same one already approved as a blood thinner

Will XARELTO be in direct competition to  Apabetalone once Apabetalone is FDA approved?

Yes and no. XARLETO will likely be able to be marketed not only as a blood thinner, but also be marketed as an agent that reduces cardiovascular events. Similar to have the SGLT2 inhibitors and GLP1 agonists (Jardiance and Victoza, respectively) were previously approved for glucose control and now can be marketed for reducing cardiovascular events after the EMPA-REG OUTCOME and LEADER trial results. So the commonality is that numberous drugs can reduce cardiovascular events. But because of these drugs are of entirely different mechanisms of actions and prescribed for patients with different risk factors, they are not all in competition with one another.
 
Is the Mechanism Of Action of XARELTO much different than Apabetalone?

Yes. Blood thinner vs. BET inhibitor. Entirely different.
 
The COMPASS trial has been ongoing since 2013 with 27,400 patients worldwide. Can there be a comparable comparison between it and Apabetalone, since Phase III BetOnMace is going through a 3-year trial and with only 2500 patients worldwide?

The number of patients in a cardiovascular outcome trial is determined by the absolute risk of the patient population over the time period studies, and the expected effect size. One trial to bring up for comparison is the CETP inhibitor anacetrapib REVEAL cardiovascular outcomes trial (https://clinicaltrials.gov/ct2/show/NCT01252953) which finishes after mid-year and has an enrollment of over 30,000. Most cardiovascular outcomes trials involve several thousand patients.....much more than the 2500 in BETonMACE. 
 
I take it that XARELTO is a small molecule?... Do we know what it costs per patient annually is as compared to Apabetalone?

Yes, Xarelto is a small molecule (https://en.wikipedia.org/wiki/Rivaroxaban). I don't know about its cost.
Bullboard Posts